Based at Granta Park, Cambridge, Biocrucible are applying their novel proprietary molecular technology platform to enhance and accelerate the behaviour and kinetics of engineered biological systems. Their technology can significantly improve the performance of many processes already currently in use throughout the life science and diagnostic industries, and they anticipate novel applications as well. Their goal is to launch life science tools and other products in the very near future adding value to existing workflows, before developing out entirely new applications.